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Angiogenesis is essential for tumour growth beyond 1–2 mm in
diameter and plays a central role in the metastatic spread of malig-
nant disease. Previous retrospective and prospective studies in
non-small-cell lung cancer (NSCLC) have clearly demonstrated
that angiogenesis, assessed by microvessel counting, is an impor-
tant prognostic factor in operable NSCLC, high microvessel
counts being associated with disease spread and a poor survival
(Giatromanolaki et al, 1996; Fontanini et al, 1997).
Vascular endothelial growth factor (VEGF) is a potent and
specific endothelial cell mitogenic and migratory, and vascular
permeability, factor. Although produced from the same gene at
least six different isoforms of 121, 145, 148, 165, 189 and 206
amino acids respectively have been identified (Ferrara and Davis-
Smyth, 1997; Whittle et al, 1999). In the normal lung, VEGF
may be expressed by bronchiolar and differentiated columnar
epithelium and alveolar macrophages. Stromal fibroblasts and
macrophages are only occasionally positive. In NSCLC tumours,
VEGF-expressing blood vessels are identified in > 50% of cases.
However, VEGF immunoreactivity is seen in < 10% of infiltrating
lymphocytes (Giatromanolaki et al, 1998; Turley et al, 1998).
Recent studies indicate that VEGF expression correlates with high
microvessel counts and a poor prognosis in NSCLC (Volm et al,
1996; Giatromanolaki et al, 1998; Oshika et al, 1998; Fontanini
et al, 1999).
Platelet-derived endothelial cell growth factor (PD-ECGF) is a
non-heparin binding angiogenic factor initially isolated from
platelets. Subsequent studies showed that PD-ECGF is a 90 kDa
homodimer and is thymidine phosphorylase (TP) (Ishikawa et al,
1989; Moghaddam and Bicknell, 1992). Transfection of the
PD-ECGF gene into transformed fibroblasts in nude mice results
in neo-angiogenesis (Ishikawa et al, 1989). Stimulation of
endothelial cell migration in vitro and enhancement of tumour
growth in vivo have also been reported (Moghaddam et al, 1995).
The precise mechanism by which PD-ECGF promotes angio-
genesis is unclear. PD-ECGF hydrolyses thymidine to thymine
and 2¢-deoxy-D-ribose-1-phosphate. 2¢-deoxy-D-ribose-1 phophate
is dephosphorylated to 2¢ deoxy-D-ribose which is angiogenic in
the chicken-chorioallantoic membrane assay (Moghaddam et al,
1995). In normal lung, PD-ECGF expression is invariably seen
in alveolar macrophages. Bronchiolar epithelium occasionally
shows positive immunoreactivity. Bronchial basal and differenti-
ated columnar cells are weakly positive. Weak immunoreactivity
is also seen in stromal fibroblasts (Giatromanolaki et al, 1997).
Recent studies indicate that tumour cell, but not stromal cell,
PD-ECGF immunoreactivity correlates with angiogenesis and
prognosis in NSCLC, high expression being associated with
angiogenesis and a poor outcome (Koukourakis et al, 1998).
The co-expression of VEGF and PD-ECGF may enhance
neovascularization in solid tumours (Toi et al, 1995; Maeda et al,
1997; Ikeda et al, 1999). In this retrospective study we report our
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expression in cancer cells (r = 0.21; P = 0.002). Co-expression of VEGF and PD-ECGF was not associated with a higher microvessel density
than VEGF or PD-ECGF only expressing tumours. Furthermore a proportion of high vascular grade tumours expressed neither growth factor.
Univariate analysis revealed tumour size, nodal status, microvessel density and VEGF and PD-ECGF expression as significant prognostic
factors. Tumour size (P < 0.02) and microvessel density (P < 0.04) remained significant on multivariate analysis. In conclusion, VEGF and
PD-ECGF are important angiogenic growth factors and have prognostic significance in NSCLC. Furthermore the study underlines the
prognostic significance of microvessel density in operable NSCLC. © 2000 Cancer Research Campaign
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series of 223 cases of NSCLC including T3 and N2 tumours. In
particular the study evaluates the impact of the co-expression of
these factors on angiogenesis and overall survival.
MATERIALS AND METHODS
Angiogenesis assessment
The JC70 monoclonal antibody (Dako) recognizing CD31
(platelet/endothelial cell adhesion molecule; PECAM-1) was used
for microvessel staining on 5-mm paraffin-embedded tissue
sections using the alkaline phosphatase/anti-alkaline phosphatase
(APAAP) procedure as previously described (Giatromanolaki
et al, 1996). Microvessel counting was used for angiogenesis
assessment. The areas of the highest vascularization were chosen
at low power (´100) and microvessel counting performed on three
chosen  ´250 fields to establish the highest density within the
tumour. The microvessel score was the sum of the vessel counts
obtained in these three fields. Microvessels adjacent to normal
lung were excluded from the appraisal. Vessels with a clearly
defined lumen or well defined linear vessel shape, but no single
endothelial cells, were counted. Microvessel scores ³ 75 defined
high vascular grade disease, and < 75, low vascular grade tumours.
This cut-off point was based on a previous study where
microvessel scores of 75 or higher defined a group of cases with
the highest death rate as compared with other cut-off points
(Giatromanolaki et al, 1998).
VEGF immunohistochemistry
VEGF immunoreactivity was evaluated employing the VG1
monoclonal antibody and the horseradish peroxidase technique as
previously described (Giatromanolaki et al, 1998; Turley et al,
1998). The VG1 monoclonal antibody, which recognizes the 121,
165 and 189 isoforms of VEGF, was raised using recombinant
VEGF 189 protein and the specificity of the antibody was
confirmed using COS cells transfected with cDNA coding for
VEGF 121, 165 and 189 protein and by Western blot studies.
Sections were dewaxed and incubated in 0.5% hydrogen peroxide
(H2O2) in methanol for 30 min. After microwaving and washing in
phosphate-buffered saline (PBS), sections were incubated with the
primary antibody for 60 min. After washing in PBS for 5 min,
sections were incubated with goat anti-mouse immunoglobulin
(1:2000) for 30 min (Dako, UK), washed again with PBS for
5 min and incubated with rabbit anti-goat immunoglobulin (1:100)
for 30 min. The peroxidase reaction was developed using
diaminobenzidine (Sigma Fast tablets) as chromogen and sections
were counterstained with haematoxylin. Normal rabbit
immunoglobulin-G was substituted for primary antibody as the
negative control (same concentration as the test antibody). Taking
into account the extent of positive staining, we divided our cases
into two categories: low reactivity (0–70% positive cells) and high
immunoreactivity (> 70% positive cells).
PD-ECGF immunoreactivity
PD-ECGF expression in NSCLC tissue sections was assessed with
the P-GF.44C monoclonal antibody as previously described
(Giatromanolaki et al, 1997; Koukourakis et al, 1998). Staining
was performed using the streptavidin-biotin-peroxidase (Dako,
UK) technique. Sections were dewaxed and incubated in 0.5%
H2O2 in methanol for 30 min. After washing in Tris-buffered
saline (TBS), sections were incubated in normal human serum
(1:10) for 20 min. Sections were then washed with TBS for 5 min
and incubated with the undiluted primary antibody for 30 min.
After washing in TBS for 5 min, sections were incubated with
biotinylated goat anti-mouse immunoglobulin (1:200) for 30 min
(Dako, UK). After incubation with the streptavidin–biotin
complex–horseradish peroxidase (Dako, UK) for 30 min, the
peroxidase reaction was developed using diaminobenzidine
(Sigma Fast tablets) as chromogen, and sections were counter-
stained with haematoxylin. Normal rabbit immunoglobulin-G was
substituted for primary antibody as the negative control. Alveolar
macrophages were used as a positive internal control
(Giatromanolaki et al, 1997).
Tumour cell component was assessed for PD-ECGF expression
by the intensity and extent of staining (Figure 1D). Two staining
patterns of PD-ECGF immunoreactivity were considered: low
reactivity (< 50% of cancer cells stained or diffuse weak reac-
tivity) and high reactivity (strong staining in > 50% cells).
Intra- and interobserver variability
In previous reports we have demonstrated that intraobserver vari-
ability was minimal for vascular grade and PD-ECGF with the
second assessment correlating with the first for all observers
(r = 0.91, P < 0.006 and r = 0.96, P < 0.001 respectively).
Similarly the interobserver variability of three investigators was
low (r = 0.94, P < 0.001 for vascular grade and r = 0.91, P < 0.008
for PD-ECGF) (Koukourakis et al, 1998). We made a similar
observation for interobserver variability for VEGF (r > 0.93,
P < 0.0001) (Giatromanolaki et al, 1998). Therefore intra- and
interobserver variability were not formally assessed in this
study.
Statistics
Statistical analysis and graphic presentation were performed using
the Stata 3.1 (Stata Corporation, Texas, USA) and the GraphPad
Prism 2.01 package. The unpaired two-tailed t-test or Fisher’s
exact test was employed to test for relationships between categor-
ical tumour variables as appropriate. Linear regression analysis
was used to assess correlation between continuous variables.
Survival curves were plotted using the method of Kaplan–Meier,
and the log-rank test was used to determine statistical differences
between life tables. A Cox proportional hazard model was used to
assess the effects of patient and tumour variables on overall
survival. A P-value < 0.05 was considered significant.
RESULTS
Of the 223 tumours studied 156 were squamous cell carcinomas
and 67 adenocarcinomas. Forty-three patients had stage 1a, 77
stage 1b, 22 stage IIa, 52 stage IIb and 29 stage IIIa NSCLC
tumours. Survival data was available for 183 patients, patients
dying within 60 days of surgery being excluded to avoid bias from
peri-operative death. The median follow-up at the time of analysis
for patients alive was 3.5 years (range 1.5–7 years).
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Eighty-nine of the 223 tumours (39.9%) were of high vascular
grade. High microvessel counts were associated with advanced
T-stage (P = 0.007) and node-positive (P = 0.0005) disease
(Table 1).
VEGF positive (high immunoreactivity) tumours accounted for
104/223 (46.6%) cases examined and were associated with high
vascular grade disease (P = 0.009) (Table 1). High PD-ECGF
tumour cell immunoreactivity was seen in 72/223 (32.3%) cases
and likewise correlated with angiogenesis (P = 0.05) (Table 1).
There was a weak positive correlation between VEGF and PD-
ECGF expression (r = 0.21, P = 0.002).
Eighteen of the 41 (44%) NSCLC tumours with high VEGF and
PD-ECGF immunoreactivity had high vascular grade disease. This
was equivalent to the proportion of VEGF only and PD-ECGF
only positive tumours associated with high microvessel counts
(31/63; 49% and 16/31; 48% respectively). As compared to
angiogenic growth factor negative disease, positive tumours were
strongly associated with high vascular grade (20/88: 22.7% vs
65/135: 48.1%; P = 0.001).
Although overall no association was found between VEGF
and/or PD-ECGF expression and stage of disease, high PD-ECGF
expression was seen more frequently in stage 1b as compared to
stage 1a NSCLC tumours (P = 0.02).
Survival analyses
Univariate analysis of survival showed that T-stage (T2 vs T1;
P = 0.01: T3 vs T2 and T1; P = 0.0001), N-stage (N2 vs N1;
P = 0.02: N2 vs N0; P = 0.0001: N1 vs N0; P = 0.002) and
vascular grade (high vs low; P = 0.0001) were the most significant
prognostic variables (Table 2) (Figure 1A). Both high tumour cell
VEGF and PD-ECGF immunoreactivity were of prognostic signi-
ficance (P = 0.02) (Table 2) (Figure 1B, C). Combined expression
of VEGF and PD-ECGF did not identify a worse prognostic
VEGF, PD-ECGF and angiogenesis in NSCLC 1429
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Figure 1 Kalpan–Meier’s survival curves. (A) VG = vascular grade: high vascular grade vs low vascular grade disease; (B). VEGF = vascular endothelial
growth factor: high VEGF vs low VEGF immunoreactive tumours; (C). TP = thymidine phosphorylase which is PD-ECGF: high TP (PD-ECGF) vs low TP
(PD-ECGF) immunoreactive tumours; (D) TP(PD-ECGF)–/VEGF– vs TP(PD-ECGF)+/VEGF– vs TP(PD-ECGF) ECGF)–/VEGF+ vs TP(PD-ECGF)+/
VEGF+ immunoreactive tumour subsets
Table 1 Correlation of vascular grade with tumour parameters in 223
patients with stage I–IIIA non-small-cell lung cancer
Microvessel score
Parameters No. of patients Low High P-value
Histology
Squamous cell 156 94 62 0.44
Adenocarcinoma 67 44 23
T-stage
T1 68 46 22
T2 135 86 49 0.007
T3 20 6 14
N-stage
N0 127 92 35
N1 77 39 38 0.0005
N2 19 7 12
Grade
1/2 109 70 39 0.44
3 114 68 46
VEGF
Negative 119 83 36 0.009
Positive 104 55 49
PD-ECGF
Negative 151 100 51 0.05
Positive 72 38 34subgroup of patients beyond that seen with VEGF or PD-ECGF
alone (Figure 1D). T-stage (P < 0.02) and vascular grade (P <
0.04) were independent predictors of outcome on multivariate
analysis when all parameters were considered (Table 3a). When
analysed as a single variable, the presence of an angiogenic growth
factor vs negative tumours approached significance in a multi-
variate model (P = 0.054) (Table 3b).
Although the numbers were relatively small the study included
sufficient patients to analyse the impact of VEGF and PD-ECGF,
and microvessel density on outcome in stage Ia to IIb disease
(stage Ia, 37; stage Ib, 67; stage IIa, 19; and stage IIb, 44 patients).
High vascular grade was associated with a poor prognosis in the
stage IIb disease subgroup only (P = 0.0005). Over-expression of
either or both of the angiogenic growth factors analysed was also
associated with a poor outcome in stage IIb disease as compared to
VEGF and PD-ECGF negative NSCLC (P = 0.02).
No association was found between histology and tumour grade
and any of the parameters evaluated.
DISCUSSION
The results support the findings of previous studies indicating that
the intensity of intratumoural angiogenesis, as assessed by tumour
microvessel counts, has prognostic significance and plays an
important role in the pathogenesis of NSCLC (Giatromanolaki et
al, 1996; Fontanini et al, 1997). This is in keeping with observa-
tions in other solid tumours including breast (Fox et al, 1995),
colorectal (Amaya et al, 1997) and gastric cancer (Maeda et al,
1996; Takahashi et al, 1998).
It is important to note, however, that not all studies have found a
positive association between microvessel density and prognosis
(Apolinario et al, 1997; Chandrachud et al, 1997; Pezzella et al,
1997). Indeed in the largest of these studies tumours with an alve-
olar pattern, with no parenchymal destruction and the alveolar
septae still present, had a worse outcome than those tumours with
an angiogenic pattern. This observation indicates that if an appro-
priate blood supply is available, an NSCLC tumour may exploit it
and grow within the lung without the need for neovascularization
(Pezzella et al, 1997). The study was in stage I NSCLC only. This
may, to some extent, account for the lack of an association
between angiogenesis and outcome as high microvessel counts are
strongly correlated with tumour size and nodal status as shown in
the present study and our earlier work (Giatromanolaki et al,
1996). Finally, although there is intense debate on the subject (Fox
et al, 1995), a recent study in lung tumours has shown consider-
able heterogeneity of vasculature in NSCLC specimens even
within blocks from the same region of the tumour. Furthermore the
periphery of the tumour, traditionally the area where blood vessels
are counted, does not always contain the highest number of vessels
(Schor et al, 1998).
A number of studies have demonstrated that VEGF expression
is associated with angiogenesis and/or has prognostic significance
in solid tumours including breast (Fox et al, 1995), colorectal
(Amaya et al, 1997), gastic (Maeda et al, 1997; Takahashi et al,
1998) and pancreatic cancer (Ikeda et al, 1999). The results of the
present work confirm previous findings of an important role for
tumour cell VEGF expression in the angiogenic process of, and as
a prognostic factor for, NSCLC (Volm et al, 1996; Giatromanolaki
et al, 1998). VEGF overexpression was not associated with a
particular stage of disease or with a negative outcome in any given
disease stage subgroup (stage Ia to IIb). However, when all 183
patients were taken into consideration, univariate analysis
revealed high VEGF immunoreactivity to be associated with a
poor prognosis (P = 0.02). The VG1 monoclonal antibody
employed in the current study detects the VEGF 121, 165 and 189
isoforms (Turley et al, 1998). The non-heparin binding VEGF 121
and the basic, heparin binding VEGF 165 are freely secreted from
producing cells whilst the longer isoforms VEGF 189 and 206 are
generally cell associated. Employing reverse transcription-poly-
merase chain reaction (RT-PCR) and in situ hybridization tech-
niques, VEGF 121, VEGF 165 and VEGF 189 have been found to
be associated with angiogenesis and/or a poor prognosis in
NSCLC (Oshika et al, 1998; Fontanini et al, 1999).
The present study confirms our earlier work demonstrating that
high PD-ECGF overexpression has a weak association with angio-
genesis and prognosis, the latter on univariate analysis only. The
findings are in keeping with the results of studies in malignant
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Table 2 Univariate analysis of all variables analysed in the study
Parameter Hazard ratio P-value
Histology
Adenocarcinoma vs squamous 1.36 0.21
T-stage
T3 vs T2 3.63 0.0001
T3 vs T1 6.29 0.0001
T2 vs T1 1.87 0.01
N-stage
N2 vs N1 2.29 0.02
N2 vs N0 4.15 0.0001
N1 vs N0 1.95 0.002
Grade
3 vs 1/2 1.36 0.14
Vascular grade
High vs low 2.34 0.0001
VEGF
Positive vs negative 1.63 0.02
PD-ECGF
Positive vs negative 1.51 0.02
Table 3a Multivariate analysis of all tumour variables analysed in the study
Hazard ratio
Variable t ratio P-value Significant?
Histology 1.254 0.212 No
T stage 2.421 0.017 Yes
N status 1.509 0.133 No
Grade 0.8698 0.386 No
CD31 2.080 0.039 Yes
VEGF 1.529 0.128 No
PD-ECGF 0.6769 0.499 No
Table 3b Multivariate analysis of variables significant at univariate analysis
but VEGF/PD-ECGF considered as a single variable
Hazard ratio
Variable t ratio P-value Significant?
T stage 2.574 0.011 Yes
N status 1.504 0.134 No
CD31 2.056 0.041 Yes
VEGF/PD-ECGF 1.941 0.054 Nodisease where PD-ECGF overexpression has been seen in a
proportion of all solid tumours studied to date including breast
(Toi et al, 1995), colorectal (Amaya et al, 1997), gastric (Maeda
et al, 1997; Takahashi et al, 1998), oesophageal (Igarashi et al,
1998) and pancreatic (Ikeda et al, 1999) cancers. In general,
PD-ECGF is associated with angiogenesis and/or advanced
disease. Furthermore overexpression may predict for poor survival
(Takebayashi et al, 1996; Ikeda et al, 1999). However, PD-ECGF
immunoreactivity, be it in the malignant, inflammatory and/or
stromal cells of the tumour, is not always associated with a poor
outcome emphasizing the relatively weak prognostic power of this
marker (Toi et al, 1995; Igarashi et al, 1998).
We observed a weak positive correlation between tumour VEGF
and PD-ECGF expression (r = 0.21; P = 0.002). Similar observa-
tions have been made in colorectal cancer (Amaya et al, 1997).
Although not seen in our study synergy between VEGF and
PD-ECGF in determining the intensity of angiogenesis has been
reported for breast, gastric and pancreatic cancer (Toi et al, 1995;
Maeda et al, 1997; Ikeda et al, 1999). A correlation between
tumour cell VEGF and PD-ECGF-positive CD68 infiltrating
inflammatory cells has been observed in gastric cancer, the vessel
count being significantly higher in tumours expressing both
growth factors as compared to those expressing each growth factor
alone (Takayashi et al, 1998). Furthermore, a significant associa-
tion between co-expression of both angiogenic factors with the
presence of hepatic metastases has been described in this disease
(Maeda et al, 1997). We found that high immunoreactivity of
either or both of the angiogenic growth factors analysed conferred
a poor prognosis in stage IIb disease (P = 0.02). This may reflect
the contribution of these growth factors to the angiogenic process
which itself is associated with a particularly poor outcome in the
stage IIb patients studied (P = 0.0005).
These findings indicate that VEGF may be a suitable target for
novel therapies in the management of NSCLC. Inhibition of
VEGF activity with monoclonal antibodies (Kim et al, 1993),
soluble VEGF receptors (Lin et al, 1998) and VEGF-receptor 2
(Flk-1/KDR) monoclonal antibodies (Skobe et al, 1997) has
shown promise in experimental in vivo models with inhibition of
angiogenesis, tumour growth and/or tumour cell invasion being
recorded.
As outlined earlier PD-ECGF is thymidine phosphorylase (TP),
an important enzyme in the activation of 5-fluorouracil (5-FU) to
fluorodeoxyuridine. TP also plays a role in converting 5-FU pro-
drugs, including 5¢-deoxy-5-fluorouridine and the novel oral fluo-
ropyrimidine carbamate, capecitabine, to their active metabolites
(Patterson et al, 1995; Budman et al, 1998). A recent report by our
group demonstrated that there was a significant improvement in
both relapse-free and overall survival in PD-ECGF/TP-positive as
compared with PD-ECGF/TP-negative breast cancer patients
treated with adjuvant cyclophosphamide, methotrexate and 5-FU
(CMF) chemotherapy. This was felt to be due not only to the acti-
vation of 5-FU but to the enhancement of the effectiveness of
methotrexate by TP (Fox et al, 1997). Given the overexpression of
PD-ECGF/TP seen in NSCLC, the combination of fluoropyrim-
idines with the more widely used cytotoxics, such as the plat-
inums, taxanes, vinca alkaloids and topoisomerase I inhibitors,
gemcitabine and ifosphamide, in the treatment of NSCLC should
be evaluated further (van Zandwijk and Giaccone, 1996).
In the present study we have clearly demonstrated that a propor-
tion of high vascular grade tumours do not express either VEGF or
PD-ECGF indicating the importance of other angiogenic factors in
this regard. Apart from the more established angiogenic growth
factors such as VEGF and PD-ECGF recent evidence has
suggested a role for tissue factor (TF) (Koomagi and Volm, 1998),
heparin-binding growth-associated molecule (HB-GAM) (Jager
et al, 1997) and CXC chemokines (Arenberg et al, 1997) in the
induction of angiogenesis in NSCLC. As such other novel anti-
angiogenic agents, including angiostatin, endostatin, TNP-470,
thalidomide and the matrix metalloproteinase inhibitors (MMPIs)
may have a role to play in the treatment of NSCLC (Harris, 1998;
Macaulay et al, 1999).
In conclusion, VEGF and PD-ECGF are important angiogenic
growth factors in NSCLC. The detection of a subset of high
vascular grade tumours not dependent on either VEGF or PD-
ECGF indicates that other angiogenic growth factors, such as
bFGF, HB-GAM and TF, may have an important role in the patho-
genesis of NSCLC.
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